Sanofi-Aventis (France) Expects FDA Letter on Heart Drug in Q2

May 5, 2009 |

1 min read

Twitter
LinkedIn
Facebook
Email
Print

Reuters -- France's Sanofi-Aventis has not yet received a letter from the U.S. health regulator giving the go-ahead for the sale of heart drug Multaq, but expects a decision during the second quarter, it said on Monday.

Twitter
LinkedIn
Facebook
Email
Print

Regulatory Europe

Food and Drug Administration (FDA) Sanofi (France)